Physicians and researchers at Winship Cancer Institute of Emory University announced they have administered the first investigational in vivo CAR-T cell therapy in the United States for relapsed and refractory multiple myeloma.
In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.
